GT Apeiron Therapeutics (‘Apeiron’) announced it has completed a $17.5 million Series A financing. Panacea Venture led the investment round with participation from Viva BioInnovator and existing investors. This is the company’s second round of financing in the last year following a Pre-A+ round in May 2021. The investment will enable the company to advance its lead CDK7 program to enter clinical trials, as well as several earlier stage programs.


Apeiron, in collaboration with Exscientia, is developing a pipeline of novel CDK therapies. Its leading asset, GTAEXS617, an orally bioavailable, highly potent and selective small-molecule inhibitor of CDK7, is currently in IND-enabling studies and pre-clinical data will be presented at this year’s AACR.


Apeiron also announced a strategic partnership with Viva Biotech (HK: 01873) under which Viva Biotech provides world-leading structure-based drug discovery expertise to enhance Apeiron’s AI-empowered innovative drug discovery and development platform.


“We are excited to welcome a group of visionary investors, embracing our journey and mission to deliver breakthrough therapies to cancer patients globally,” said Dr. Mingxi Li, Co-Founder and CEO of Apeiron, “Over the past two years, our team has built a unique pipeline of precision oncology therapies, focusing on CDKs and synthetic lethality. We will continue strengthen our integrated drug discovery platform with AI and structural biology.”



About GT Apeiron Therapeutics


Apeiron is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, please visit 



About Viva Biotech Holdings


Established in 2008, Viva Biotech (01873.HK) provides one-stop services from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. Leveraging the technical advantages in the field of Structure-based Drug Discovery (SBDD), we provide leading CRO drug discovery services and CMC / CDMO services throughout the whole drug production process to global biopharmaceutical clients. At the same time, we focus on finding and investing in high potential biotech start-ups, solve unmet clinical medical needs in the form of EFS (service for equity), and continue to build an open cooperation platform and win-win ecosystem for biotech innovation.


As of December 31, 2021, Viva Biotech has provided drug R&D and production services to 1,820 biotech and pharmaceutical clients around the world. We have invested and incubated 87 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva’s platform.